ATEZOLIZUMAB

Information current as at: 1 June 2026

PBAC meeting date: July 2026
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Tecentriq SC®
Form and strength:
  • Solution for subcutaneous injection 1875 mg in 15 mL
Submission sponsor:
LICENSED STERILE COMPOUNDERS OF AUSTRALIA LIMITED
Condition/indication:
(therapeutic use)
  • Advanced (unresectable) Barcelona Clinic Liver Cancer Stage B or Stage C hepatocellular carcinoma; Extensive-stage small cell lung cancer; Resected early stage (Stage II to IIIA) non-small cell lung cancer; Locally advanced or metastatic non-small cell lung cancer; Stage IV (metastatic) non-small cell lung cancer
Listing requested:
To request that the listings for the subcutaneous form of atezolizumab transition to the Section 100 (Efficient Funding of Chemotherapy) program.
Funding program:
PBS Section 100 (Efficient funding of Chemotherapy)
Request authority level:
Authority Required
PBAC Submission type:
New PBS listing (–)
Comment:
Withdrawn
Other PBAC consideration:
--

Progress Details

Submission received for:
July 2026 PBAC meeting
Opportunity for consumer comment:
Open 25/03/2026 and close 20/05/2026 (see PBS Website)
3PBAC meeting:
Has not yet occurred
PBAC outcome published:
Pending PBAC outcome (see PBAC Outcomes)
Lodgement of required documentation:
Not applicable
Agreement to listing arrangements:
Not applicable
Government processes:
Not applicable
Medicine listed on the PBS:
Not applicable
Glossary

PBAC Outcome

PBAC Recommendation:
Please see the Outcomes from the relevant meeting for more information
Case ID
1211
Page last updated
31 May 2026
Return to the Medicine Status Listing
v.9.19